Pre-exposure prophylaxis drug for HIV prepared for annual administration
Vamshi Jogiraju and colleagues at Gilead Sciences reported success in a phase I clinical trial of lenacapavir as a single-shot, yearly pre-exposure prophylaxis for HIV infection. As follows…